LAS VEGAS--(BUSINESS WIRE)--Ault Global Holdings, Inc. (NYSE American: DPW), a diversified holding company (the “Company”), announced that as of January 29, 2021, the Company had purchased an aggregate of 295,000 shares of common stock or 9.96% equity interest in NTN Buzztime, Inc. (NYSE American: NTN) (“NTN”). The Company purchased the shares of common stock at a weighted average price of $3.42 per share in the open market, for total gross proceeds of $1,010,095. For further information, see the Schedule 13D filed by the Company on January 29, 2021. Milton “Todd” Ault, III, the Executive Chairman of the Company, stated, “We believe NTN’s assets, particularly its gaming assets an
SC 13G - NTN BUZZTIME INC (0000748592) (Subject)
SC 13G/A - NTN BUZZTIME INC (0000748592) (Subject)
8-K - Brooklyn ImmunoTherapeutics, Inc. (0000748592) (Filer)
8-K - NTN BUZZTIME INC (0000748592) (Filer)
10-K - NTN BUZZTIME INC (0000748592) (Filer)
8-K - NTN BUZZTIME INC (0000748592) (Filer)
425 - NTN BUZZTIME INC (0000748592) (Subject)
8-K - NTN BUZZTIME INC (0000748592) (Filer)
425 - NTN BUZZTIME INC (0000748592) (Subject)
8-K - NTN BUZZTIME INC (0000748592) (Filer)
425 - NTN BUZZTIME INC (0000748592) (Subject)
8-K - NTN BUZZTIME INC (0000748592) (Filer)
CARLSBAD, Calif., March 23, 2021 /PRNewswire/ -- NTN Buzztime, Inc. (NYSE American: NTN) today announced that it plans to effect a one for two reverse stock split of its outstanding shares of common stock immediately prior to the closing of the merger with Brooklyn ImmunoTherapeutics LLC, which is anticipated to occur on March 25, 2021. The shares of common stock of the resulting company is expected to commence trading on March 26, 2021 on the NYSE American under the trading symbol "BTX". As previously announced, at special meeting of stockholders of NTN held on March 15, 2021, NTN's stockholders approved, among other proposals, the issuance of shares of NTN's common stock to the members of
CARLSBAD, Calif., March 15, 2021 /PRNewswire/ -- NTN Buzztime, Inc. (NYSE American: NTN) today announced that its stockholders have approved the proposed merger between NTN and Brooklyn ImmunoTherapeutics LLC. The proposed merger remains subject to further customary closing conditions and regulatory approvals. NTN expects that the merger will close in the next two weeks. NTN reported that at the meeting, the following proposals were approved: (i) Proposal 1, relating to the issuance of shares of NTN's common stock to the members of Brooklyn pursuant to the merger and the change of control resulting therefrom, (ii) Proposal 2, authorizing an amendment to NTN's certificate of incorporation to
CARLSBAD, Calif., March 8, 2021 /PRNewswire/ -- NTN Buzztime, Inc. (NYSE American: NTN) today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. ("ISS") recommends that NTN stockholders vote "FOR" ALL PROPOSALS to be considered and voted on at the March 15, 2021 special meeting of stockholders, all of which relate to the proposed merger involving NTN and Brooklyn ImmunoTherapeutics LLC ("Brooklyn") and the proposed sale of NTN's assets to eGames.com Holdings LLC ("eGames.com"). "We are very pleased that ISS supports our board's recommendation that stockholders vote "FOR" the proposals related to the merger and asset sale," said Allen Wolff, NTN's
CARLSBAD, Calif., March 1, 2021 /PRNewswire/ -- The board of directors of NTN Buzztime, Inc. (NYSE American: NTN) unanimously urges NTN's stockholders to vote FOR ALL the proposals to be voted on at the March 15, 2021 special meeting of stockholders, all of which relate to the proposed merger involving NTN and Brooklyn ImmunoTherapeutics LLC ("Brooklyn") and the proposed sale of NTN's assets to eGames.com Holdings LLC ("eGames.com"). The NTN board of directors reiterates the following: The negative impact of the COVID-19 pandemic on the restaurant and bar industry was abrupt and substantial, and NTN's business, cash flows from operations and liquidity has suffered, and continues to suffer,
LAS VEGAS--(BUSINESS WIRE)--Ault Global Holdings, Inc. (NYSE American: DPW), a diversified holding company (the “Company”), announced that as of January 29, 2021, the Company had purchased an aggregate of 295,000 shares of common stock or 9.96% equity interest in NTN Buzztime, Inc. (NYSE American: NTN) (“NTN”). The Company purchased the shares of common stock at a weighted average price of $3.42 per share in the open market, for total gross proceeds of $1,010,095. For further information, see the Schedule 13D filed by the Company on January 29, 2021. Milton “Todd” Ault, III, the Executive Chairman of the Company, stated, “We believe NTN’s assets, particularly its gaming assets an
CARLSBAD, Calif., Feb. 3, 2021 /PRNewswire/ -- NTN Buzztime, Inc. (NYSE American: NTN), today announced that its registration statement on Form S-4 relating to the proposed merger involving NTN and Brooklyn ImmunoTherapeutics LLC ("Brooklyn") and the proposed sale of NTN's assets to eGames.com Holdings LLC ("eGames.com") has been declared effective by the Securities and Exchange Commission. NTN will be holding its special meeting of stockholders to consider the merger, the asset sale and related proposals on March 15, 2021 at 9:00 a.m., Pacific Time, unless postponed or adjourned to a later date or time. Additional details regarding the proposals and the special meeting will be made avail
CARLSBAD, Calif., Jan. 15, 2021 /PRNewswire/ -- NTN Buzztime, Inc. (NYSE American: NTN), announced it received a letter from the NYSE Regulation stating that it is not in compliance with NYSE American LLC continued listing standards. Specifically, the Company is not in compliance with Section 704 of the NYSE American Company Guide because it did not hold an annual meeting during the fiscal year ended December 31, 2020. NTN continues to not be in compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide because it reported stockholders equity of less than $2 million, $4 million and $6 million as of June 30, 2020, March 31, 2020 and December 31, 2019, respectively. As a resu
4 - Brooklyn ImmunoTherapeutics, Inc. (0000748592) (Issuer)
4 - Brooklyn ImmunoTherapeutics, Inc. (0000748592) (Issuer)
4 - NTN BUZZTIME INC (0000748592) (Issuer)
4 - NTN BUZZTIME INC (0000748592) (Issuer)
4 - NTN BUZZTIME INC (0000748592) (Issuer)
4 - NTN BUZZTIME INC (0000748592) (Issuer)
4 - NTN BUZZTIME INC (0000748592) (Issuer)
4 - NTN BUZZTIME INC (0000748592) (Issuer)